CD19 and neoplasm: FT596 incorporates an NKG2D-2B4ζ CAR targeting CD19 that enhances anti-tumor activity against CD19-expressing B cells, an hnCD16, and a recombinant fusion of IL-15 and IL-15 receptor alpha (IL-15RF) for cytokine-autonomous persistence.